TY - JOUR AU - Lundin, K. E. AU - Gissberg, O. AU - Smith, C. E. PY - 2015 DA - 2015// TI - Oligonucleotide therapies: the past and the present JO - Hum Gene Ther VL - 26 UR - https://doi.org/10.1089/hum.2015.070 DO - 10.1089/hum.2015.070 ID - Lundin2015 ER - TY - JOUR AU - Wittrup, A. AU - Lieberman, J. PY - 2015 DA - 2015// TI - Knocking down disease: a progress report on siRNA therapeutics JO - Nat Rev Genet VL - 16 UR - https://doi.org/10.1038/nrg3978 DO - 10.1038/nrg3978 ID - Wittrup2015 ER - TY - JOUR AU - Fellmann, C. AU - Gowen, B. G. AU - Lin, P. -. C. AU - Doudna, J. A. AU - Corn, J. E. PY - 2017 DA - 2017// TI - Cornerstones of CRISPR–Cas in drug discovery and therapy JO - Nat Rev Drug Discov VL - 16 UR - https://doi.org/10.1038/nrd.2016.238 DO - 10.1038/nrd.2016.238 ID - Fellmann2017 ER - TY - JOUR AU - Smidt, P. C. AU - Doan, T. L. AU - Sd, F. AU - TJv, B. PY - 1991 DA - 1991// TI - Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution JO - Nucleic Acids Res VL - 19 UR - https://doi.org/10.1093/nar/19.17.4695 DO - 10.1093/nar/19.17.4695 ID - Smidt1991 ER - TY - JOUR AU - Jackson, A. L. AU - Bartz, S. R. AU - Schelter, J. AU - Kobayashi, S. V. AU - Burchard, J. AU - Mao, M. PY - 2003 DA - 2003// TI - Expression profiling reveals off-target gene regulation by RNAi JO - Nat Biotechnol VL - 21 UR - https://doi.org/10.1038/nbt831 DO - 10.1038/nbt831 ID - Jackson2003 ER - TY - JOUR AU - Yin, H. AU - Kauffman, K. J. AU - Anderson, D. G. PY - 2017 DA - 2017// TI - Delivery technologies for genome editing JO - Nat Rev Drug Discov VL - 16 UR - https://doi.org/10.1038/nrd.2016.280 DO - 10.1038/nrd.2016.280 ID - Yin2017 ER - TY - JOUR AU - Stein, C. A. AU - Castanotto, D. PY - 2017 DA - 2017// TI - FDA-approved oligonucleotide therapies in 2017 JO - Mol Ther VL - 25 UR - https://doi.org/10.1016/j.ymthe.2017.03.023 DO - 10.1016/j.ymthe.2017.03.023 ID - Stein2017 ER - TY - JOUR AU - Yamakawa, K. AU - Nakano-Narusawa, Y. AU - Hashimoto, N. AU - Yokohira, M. AU - Matsuda, Y. PY - 2019 DA - 2019// TI - Development and clinical trials of nucleic acid medicines for pancreatic cancer treatment JO - Int J Mol Sci VL - 20 UR - https://doi.org/10.3390/ijms20174224 DO - 10.3390/ijms20174224 ID - Yamakawa2019 ER - TY - JOUR AU - Lai, A. C. AU - Crews, C. M. PY - 2017 DA - 2017// TI - Induced protein degradation: an emerging drug discovery paradigm JO - Nat Rev Drug Discov VL - 16 UR - https://doi.org/10.1038/nrd.2016.211 DO - 10.1038/nrd.2016.211 ID - Lai2017 ER - TY - JOUR AU - Wakeling, A. E. AU - Dukes, M. AU - Bowler, J. PY - 1991 DA - 1991// TI - A potent specific pure antiestrogen with clinical potential JO - Cancer Res VL - 51 ID - Wakeling1991 ER - TY - JOUR AU - Leo, A. AU - Jerusalem, G. AU - Petruzelka, L. AU - Torres, R. AU - Bondarenko, I. N. AU - Khasanov, R. PY - 2010 DA - 2010// TI - Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.8415 DO - 10.1200/JCO.2010.28.8415 ID - Leo2010 ER - TY - JOUR AU - Bross, P. F. AU - Cohen, M. H. AU - Williams, G. A. AU - Pazdur, R. PY - 2002 DA - 2002// TI - FDA drug approval summaries: fulvestrant JO - Oncologist VL - 7 UR - https://doi.org/10.1634/theoncologist.7-6-477 DO - 10.1634/theoncologist.7-6-477 ID - Bross2002 ER - TY - JOUR AU - Wu, Y. -. L. AU - Yang, X. AU - Ren, Z. AU - McDonnell, D. P. AU - Norris, J. D. AU - Willson, T. M. PY - 2005 DA - 2005// TI - Structural basis for an unexpected mode of SERM-mediated ER antagonism JO - Mol Cell VL - 18 UR - https://doi.org/10.1016/j.molcel.2005.04.014 DO - 10.1016/j.molcel.2005.04.014 ID - Wu2005 ER - TY - JOUR AU - Neklesa, T. K. AU - Tae, H. S. AU - Schneekloth, A. R. AU - Stulberg, M. J. AU - Corson, T. W. AU - Sundberg, T. B. PY - 2011 DA - 2011// TI - Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins JO - Nat Chem Biol VL - 7 UR - https://doi.org/10.1038/nchembio.597 DO - 10.1038/nchembio.597 ID - Neklesa2011 ER - TY - JOUR AU - Sakamoto, K. M. AU - Kim, K. B. AU - Kumagai, A. AU - Mercurio, F. AU - Crews, C. M. AU - Deshaies, R. J. PY - 2001 DA - 2001// TI - Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation JO - Proc Natl Acad Sci VL - 98 UR - https://doi.org/10.1073/pnas.141230798 DO - 10.1073/pnas.141230798 ID - Sakamoto2001 ER - TY - JOUR AU - Kubota, H. PY - 2009 DA - 2009// TI - Quality control against misfolded proteins in the cytosol: a network for cell survival JO - J Biochem VL - 146 UR - https://doi.org/10.1093/jb/mvp139 DO - 10.1093/jb/mvp139 ID - Kubota2009 ER - TY - JOUR AU - Long, M. J. AU - Gollapalli, D. R. AU - Hedstrom, L. PY - 2012 DA - 2012// TI - Inhibitor mediated protein degradation JO - Chem Biol VL - 19 UR - https://doi.org/10.1016/j.chembiol.2012.04.008 DO - 10.1016/j.chembiol.2012.04.008 ID - Long2012 ER - TY - JOUR AU - Gao, N. AU - Chu, T. -. T. AU - Li, Q. -. Q. AU - Lim, Y. -. J. AU - Qiu, T. AU - Ma, M. -. R. PY - 2017 DA - 2017// TI - Hydrophobic tagging-mediated degradation of Alzheimer's disease related tau JO - RSC Adv VL - 7 UR - https://doi.org/10.1039/C7RA05347A DO - 10.1039/C7RA05347A ID - Gao2017 ER - TY - JOUR AU - Coffey, R. T. AU - Shi, Y. AU - Long, M. J. AU - Marr, M. T. AU - Hedstrom, L. PY - 2016 DA - 2016// TI - Ubiquilin-mediated small molecule inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling JO - J Biol Chem VL - 291 UR - https://doi.org/10.1074/jbc.M115.691584 DO - 10.1074/jbc.M115.691584 ID - Coffey2016 ER - TY - JOUR AU - Chamberlain, P. P. AU - Hamann, L. G. PY - 2019 DA - 2019// TI - Development of targeted protein degradation therapeutics JO - Nat Chem Biol VL - 15 UR - https://doi.org/10.1038/s41589-019-0362-y DO - 10.1038/s41589-019-0362-y ID - Chamberlain2019 ER - TY - STD TI - Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019;18:1–15. ID - ref21 ER - TY - JOUR AU - Bushweller, J. H. PY - 2019 DA - 2019// TI - Targeting transcription factors in cancer—from undruggable to reality JO - Nat Rev Cancer VL - 19 UR - https://doi.org/10.1038/s41568-019-0196-7 DO - 10.1038/s41568-019-0196-7 ID - Bushweller2019 ER - TY - STD TI - Pettersson M, Crews CM. Proteolysis TArgeting chimeras (PROTACs)—past, present and future. Drug Discov Today Technol. 2019;31:15–27. ID - ref23 ER - TY - JOUR AU - Salami, J. AU - Crews, C. M. PY - 2017 DA - 2017// TI - Waste disposal—an attractive strategy for cancer therapy JO - Science VL - 355 UR - https://doi.org/10.1126/science.aam7340 DO - 10.1126/science.aam7340 ID - Salami2017 ER - TY - JOUR AU - Sakamoto, K. M. PY - 2010 DA - 2010// TI - Protacs for treatment of cancer JO - Pediatr Res VL - 67 UR - https://doi.org/10.1203/PDR.0b013e3181d35017 DO - 10.1203/PDR.0b013e3181d35017 ID - Sakamoto2010 ER - TY - JOUR AU - Ohoka, N. AU - Shibata, N. AU - Hattori, T. AU - Naito, M. PY - 2016 DA - 2016// TI - Protein knockdown technology: application of ubiquitin ligase to cancer therapy JO - Curr Cancer Drug Targets VL - 16 UR - https://doi.org/10.2174/1568009616666151112122502 DO - 10.2174/1568009616666151112122502 ID - Ohoka2016 ER - TY - JOUR AU - Gadd, M. S. AU - Testa, A. AU - Lucas, X. AU - Chan, K. -. H. AU - Chen, W. AU - Lamont, D. J. PY - 2017 DA - 2017// TI - Structural basis of PROTAC cooperative recognition for selective protein degradation JO - Nat Chem Biol VL - 13 UR - https://doi.org/10.1038/nchembio.2329 DO - 10.1038/nchembio.2329 ID - Gadd2017 ER - TY - JOUR AU - Deshaies, R. PY - 1999 DA - 1999// TI - SCF and Cullin/ring H2-based ubiquitin ligases JO - Annu Rev Cell Dev Biol VL - 15 UR - https://doi.org/10.1146/annurev.cellbio.15.1.435 DO - 10.1146/annurev.cellbio.15.1.435 ID - Deshaies1999 ER - TY - STD TI - Kaelin W. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol. 2005;70:159–66. ID - ref29 ER - TY - STD TI - Shi Q, Chen L. Cereblon: a protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation. J Immunol Res. 2017;2017:1–8. ID - ref30 ER - TY - JOUR AU - Silke, J. AU - Meier, P. PY - 2013 DA - 2013// TI - Inhibitor of apoptosis (IAP) proteins–modulators of cell death and inflammation JO - Cold Spring Harb Perspect Biol VL - 5 UR - https://doi.org/10.1101/cshperspect.a008730 DO - 10.1101/cshperspect.a008730 ID - Silke2013 ER - TY - JOUR AU - Iwakuma, T. AU - Lozano, G. PY - 2003 DA - 2003// TI - MDM2, an introduction JO - Mol Cancer Res VL - 1 ID - Iwakuma2003 ER - TY - JOUR AU - Lu, J. AU - Qian, Y. AU - Altieri, M. AU - Dong, H. AU - Wang, J. AU - Raina, K. PY - 2015 DA - 2015// TI - Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4 JO - Chem Biol VL - 22 UR - https://doi.org/10.1016/j.chembiol.2015.05.009 DO - 10.1016/j.chembiol.2015.05.009 ID - Lu2015 ER - TY - STD TI - White ME, Fenger JM, Carson WE III. Emerging roles of and therapeutic strategies targeting BRD4 in cancer. Cell Immunol. 2019;337:48–53. ID - ref34 ER - TY - JOUR AU - Bradner, J. E. AU - Hnisz, D. AU - Young, R. A. PY - 2017 DA - 2017// TI - Transcriptional addiction in cancer JO - Cell VL - 168 UR - https://doi.org/10.1016/j.cell.2016.12.013 DO - 10.1016/j.cell.2016.12.013 ID - Bradner2017 ER - TY - JOUR AU - Shi, C. AU - Zhang, H. AU - Wang, P. AU - Wang, K. AU - Xu, D. AU - Wang, H. PY - 2019 DA - 2019// TI - PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis JO - Cell Death Dis VL - 10 UR - https://doi.org/10.1038/s41419-019-2022-2 DO - 10.1038/s41419-019-2022-2 ID - Shi2019 ER - TY - JOUR AU - Winter, G. E. AU - Buckley, D. L. AU - Paulk, J. AU - Roberts, J. M. AU - Souza, A. AU - Dhe-Paganon, S. PY - 2015 DA - 2015// TI - Phthalimide conjugation as a strategy for in vivo target protein degradation JO - Science VL - 348 UR - https://doi.org/10.1126/science.aab1433 DO - 10.1126/science.aab1433 ID - Winter2015 ER - TY - JOUR AU - Zengerle, M. AU - Chan, K. -. H. AU - Ciulli, A. PY - 2015 DA - 2015// TI - Selective small molecule induced degradation of the BET bromodomain protein BRD4 JO - ACS Chem Biol VL - 10 UR - https://doi.org/10.1021/acschembio.5b00216 DO - 10.1021/acschembio.5b00216 ID - Zengerle2015 ER - TY - JOUR AU - Mar, N. -. L. M. AU - Nieto-Jimenez, C. AU - Burgos, M. AU - Gómez-Juárez, M. AU - Montero, J. C. AU - Esparís-Ogando, A. PY - 2019 DA - 2019// TI - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-018-1018-6 DO - 10.1186/s13046-018-1018-6 ID - Mar2019 ER - TY - STD TI - Testa A, Hughes SJ, Lucas X, Wright JE, Ciulli A. Structure-based design of a macrocyclic PROTAC. Angew Chem Int Ed. 2020;59:1727–34. ID - ref40 ER - TY - JOUR AU - Raina, K. AU - Lu, J. AU - Qian, Y. AU - Altieri, M. AU - Gordon, D. AU - Rossi, A. M. K. PY - 2016 DA - 2016// TI - PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer JO - Proc Natl Acad Sci VL - 113 UR - https://doi.org/10.1073/pnas.1521738113 DO - 10.1073/pnas.1521738113 ID - Raina2016 ER - TY - JOUR AU - Saenz, D. T. AU - Fiskus, W. AU - Qian, Y. AU - Manshouri, T. AU - Rajapakshe, K. AU - Raina, K. PY - 2017 DA - 2017// TI - Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2016.393 DO - 10.1038/leu.2016.393 ID - Saenz2017 ER - TY - JOUR AU - Pfaff, P. AU - Samarasinghe, K. T. AU - Crews, C. M. AU - Carreira, E. M. PY - 2019 DA - 2019// TI - Reversible spatiotemporal control of induced protein degradation by bistable photoPROTACs JO - ACS Cent Sci VL - 5 UR - https://doi.org/10.1021/acscentsci.9b00713 DO - 10.1021/acscentsci.9b00713 ID - Pfaff2019 ER - TY - STD TI - Pillow TH, Adhikari P, Blake RA, Chen J, Del Rosario G, Deshmukh G, et al. Antibody conjugation of a chimeric BET degrader enables in vivo activity. ChemMedChem. 2020;15(1):17–25. ID - ref44 ER - TY - JOUR AU - Wurz, R. P. AU - Dellamaggiore, K. AU - Dou, H. AU - Javier, N. AU - Lo, M. -. C. AU - McCarter, J. D. PY - 2018 DA - 2018// TI - A “click chemistry platform” for the rapid synthesis of bispecific molecules for inducing protein degradation JO - J Med Chem VL - 61 UR - https://doi.org/10.1021/acs.jmedchem.6b01781 DO - 10.1021/acs.jmedchem.6b01781 ID - Wurz2018 ER - TY - JOUR AU - Zhang, X. AU - Lee, H. C. AU - Shirazi, F. AU - Baladandayuthapani, V. AU - Lin, H. AU - Kuiatse, I. PY - 2018 DA - 2018// TI - Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma JO - Leukemia VL - 32 UR - https://doi.org/10.1038/s41375-018-0044-x DO - 10.1038/s41375-018-0044-x ID - Zhang2018 ER - TY - JOUR AU - Rathod, D. AU - Fu, Y. AU - Patel, K. PY - 2019 DA - 2019// TI - BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: preformulation studies, formulation development and in vitro evaluation JO - Eur J Pharm Sci VL - 138 UR - https://doi.org/10.1016/j.ejps.2019.105039 DO - 10.1016/j.ejps.2019.105039 ID - Rathod2019 ER - TY - JOUR AU - Winter, G. E. AU - Mayer, A. AU - Buckley, D. L. AU - Erb, M. A. AU - Roderick, J. E. AU - Vittori, S. AU - Reyes, J. M. AU - Iulio, J. AU - Souza, A. AU - Ott, C. J. PY - 2017 DA - 2017// TI - BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment JO - Mol Cell VL - 67 UR - https://doi.org/10.1016/j.molcel.2017.06.004 DO - 10.1016/j.molcel.2017.06.004 ID - Winter2017 ER - TY - STD TI - Reynders M, Matsuura B, Bérouti M, Simoneschi D, Marzio A, Pagano M, et al. PHOTACs enable optical control of protein degradation. Sci Adv. 2020;6(8):eaay5064. ID - ref49 ER - TY - JOUR AU - Xue, G. AU - Wang, K. AU - Zhou, D. AU - Zhong, H. AU - Pan, Z. PY - 2019 DA - 2019// TI - Light-induced protein degradation with photocaged PROTACs JO - J Am Chem Soc VL - 141 UR - https://doi.org/10.1021/jacs.9b06422 DO - 10.1021/jacs.9b06422 ID - Xue2019 ER - TY - STD TI - Naro Y, Darrah K, Deiters A. Optical control of small molecule-induced protein degradation. J Am Chem Soc. 2020;142(5):2193–97. ID - ref51 ER - TY - JOUR AU - Zhou, B. AU - Hu, J. AU - Xu, F. AU - Chen, Z. AU - Bai, L. AU - Fernandez-Salas, E. PY - 2018 DA - 2018// TI - Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression JO - J Med Chem VL - 61 UR - https://doi.org/10.1021/acs.jmedchem.6b01816 DO - 10.1021/acs.jmedchem.6b01816 ID - Zhou2018 ER - TY - JOUR AU - Bai, L. AU - Zhou, B. AU - Yang, C. -. Y. AU - Ji, J. AU - McEachern, D. AU - Przybranowski, S. PY - 2017 DA - 2017// TI - Targeted degradation of BET proteins in triple-negative breast cancer JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-2622 DO - 10.1158/0008-5472.CAN-16-2622 ID - Bai2017 ER - TY - JOUR AU - Qin, C. AU - Hu, Y. AU - Zhou, B. AU - Fernandez-Salas, E. AU - Yang, C. -. Y. AU - Liu, L. PY - 2018 DA - 2018// TI - Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression JO - J Med Chem VL - 61 UR - https://doi.org/10.1021/acs.jmedchem.8b00506 DO - 10.1021/acs.jmedchem.8b00506 ID - Qin2018 ER - TY - JOUR AU - Wang, S. AU - Song, Y. AU - Wang, Y. AU - Gao, Y. AU - Yu, S. AU - Zhao, Q. PY - 2018 DA - 2018// TI - Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation JO - Chem Res Chin Univ VL - 34 UR - https://doi.org/10.1007/s40242-018-7272-5 DO - 10.1007/s40242-018-7272-5 ID - Wang2018 ER - TY - JOUR AU - Lebraud, H. AU - Wright, D. J. AU - Johnson, C. N. AU - Heightman, T. D. PY - 2016 DA - 2016// TI - Protein degradation by in-cell self-assembly of proteolysis targeting chimeras JO - ACS central science VL - 2 UR - https://doi.org/10.1021/acscentsci.6b00280 DO - 10.1021/acscentsci.6b00280 ID - Lebraud2016 ER - TY - JOUR AU - Ohoka, N. AU - Okuhira, K. AU - Ito, M. AU - Nagai, K. AU - Shibata, N. AU - Hattori, T. PY - 2017 DA - 2017// TI - In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs) JO - J Biol Chem VL - 292 UR - https://doi.org/10.1074/jbc.M116.768853 DO - 10.1074/jbc.M116.768853 ID - Ohoka2017 ER - TY - JOUR AU - Hines, J. AU - Lartigue, S. AU - Dong, H. AU - Qian, Y. AU - Crews, C. M. PY - 2019 DA - 2019// TI - MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53 JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-18-2918 DO - 10.1158/0008-5472.CAN-18-2918 ID - Hines2019 ER - TY - JOUR AU - Mohamed, A. J. AU - Yu, L. AU - Bäckesjö, C. M. AU - Vargas, L. AU - Faryal, R. AU - Aints, A. PY - 2009 DA - 2009// TI - Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain JO - Immunol Rev VL - 228 UR - https://doi.org/10.1111/j.1600-065X.2008.00741.x DO - 10.1111/j.1600-065X.2008.00741.x ID - Mohamed2009 ER - TY - STD TI - Young RM, Shaffer AL III, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):77–85. ID - ref60 ER - TY - JOUR AU - Huang, H. -. T. AU - Dobrovolsky, D. AU - Paulk, J. AU - Yang, G. AU - Weisberg, E. L. AU - Doctor, Z. M. AU - Buckley, D. L. AU - Cho, J. -. H. AU - Ko, E. AU - Jang, J. PY - 2018 DA - 2018// TI - A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader JO - Cell Chem Biol VL - 25 UR - https://doi.org/10.1016/j.chembiol.2017.10.005 DO - 10.1016/j.chembiol.2017.10.005 ID - Huang2018 ER - TY - JOUR AU - Dobrovolsky, D. AU - Wang, E. S. AU - Morrow, S. AU - Leahy, C. AU - Faust, T. AU - Nowak, R. P. PY - 2019 DA - 2019// TI - Bruton tyrosine kinase degradation as a therapeutic strategy for cancer JO - Blood, The Journal of the American Society of Hematology VL - 133 ID - Dobrovolsky2019 ER - TY - JOUR AU - Buhimschi, A. D. AU - Armstrong, H. A. AU - Toure, M. AU - Jaime-Figueroa, S. AU - Chen, T. L. AU - Lehman, A. M. PY - 2018 DA - 2018// TI - Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation JO - Biochemistry VL - 57 UR - https://doi.org/10.1021/acs.biochem.8b00391 DO - 10.1021/acs.biochem.8b00391 ID - Buhimschi2018 ER - TY - JOUR AU - Sun, Y. AU - Zhao, X. AU - Ding, N. AU - Gao, H. AU - Wu, Y. AU - Yang, Y. PY - 2018 DA - 2018// TI - PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies JO - Cell Res VL - 28 UR - https://doi.org/10.1038/s41422-018-0055-1 DO - 10.1038/s41422-018-0055-1 ID - Sun2018 ER - TY - JOUR AU - Sun, Y. AU - Ding, N. AU - Song, Y. AU - Yang, Z. AU - Liu, W. AU - Zhu, J. PY - 2019 DA - 2019// TI - Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas JO - Leukemia VL - 33 UR - https://doi.org/10.1038/s41375-019-0440-x DO - 10.1038/s41375-019-0440-x ID - Sun2019 ER - TY - JOUR AU - Zorba, A. AU - Nguyen, C. AU - Xu, Y. AU - Starr, J. AU - Borzilleri, K. AU - Smith, J. PY - 2018 DA - 2018// TI - Delineating the role of cooperativity in the design of potent PROTACs for BTK JO - Proc Natl Acad Sci VL - 115 UR - https://doi.org/10.1073/pnas.1803662115 DO - 10.1073/pnas.1803662115 ID - Zorba2018 ER - TY - JOUR AU - Tinworth, C. P. AU - Lithgow, H. AU - Dittus, L. AU - Bassi, Z. I. AU - Hughes, S. E. AU - Muelbaier, M. PY - 2019 DA - 2019// TI - PROTAC-mediated degradation of Bruton’s tyrosine kinase is inhibited by covalent binding JO - ACS Chem Biol VL - 14 UR - https://doi.org/10.1021/acschembio.8b01094 DO - 10.1021/acschembio.8b01094 ID - Tinworth2019 ER - TY - JOUR AU - Quintás-Cardama, A. AU - Cortes, J. PY - 2009 DA - 2009// TI - Molecular biology of bcr-abl1–positive chronic myeloid leukemia JO - Blood, The Journal of the American Society of Hematology VL - 113 ID - Quintás-Cardama2009 ER - TY - JOUR AU - Hantschel, O. AU - Warsch, W. AU - Eckelhart, E. AU - Kaupe, I. AU - Grebien, F. AU - Wagner, K. -. U. PY - 2012 DA - 2012// TI - BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia JO - Nat Chem Biol VL - 8 UR - https://doi.org/10.1038/nchembio.775 DO - 10.1038/nchembio.775 ID - Hantschel2012 ER - TY - JOUR AU - Lai, A. C. AU - Toure, M. AU - Hellerschmied, D. AU - Salami, J. AU - Jaime-Figueroa, S. AU - Ko, E. PY - 2016 DA - 2016// TI - Modular PROTAC design for the degradation of oncogenic BCR-ABL JO - Angew Chem Int Ed VL - 55 UR - https://doi.org/10.1002/anie.201507634 DO - 10.1002/anie.201507634 ID - Lai2016 ER - TY - JOUR AU - Burslem, G. M. AU - Schultz, A. R. AU - Bondeson, D. P. AU - Eide, C. A. AU - Stevens, S. L. S. AU - Druker, B. J. PY - 2019 DA - 2019// TI - Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-19-1236 DO - 10.1158/0008-5472.CAN-19-1236 ID - Burslem2019 ER - TY - JOUR AU - Demizu, Y. AU - Shibata, N. AU - Hattori, T. AU - Ohoka, N. AU - Motoi, H. AU - Misawa, T. PY - 2016 DA - 2016// TI - Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand JO - Bioorg Med Chem Lett VL - 26 UR - https://doi.org/10.1016/j.bmcl.2016.09.041 DO - 10.1016/j.bmcl.2016.09.041 ID - Demizu2016 ER - TY - JOUR AU - Shibata, N. AU - Miyamoto, N. AU - Nagai, K. AU - Shimokawa, K. AU - Sameshima, T. AU - Ohoka, N. PY - 2017 DA - 2017// TI - Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands JO - Cancer Sci VL - 108 UR - https://doi.org/10.1111/cas.13284 DO - 10.1111/cas.13284 ID - Shibata2017 ER - TY - JOUR AU - Kozopas, K. M. AU - Yang, T. AU - Buchan, H. L. AU - Zhou, P. AU - Craig, R. W. PY - 1993 DA - 1993// TI - MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2 JO - Proc Natl Acad Sci VL - 90 UR - https://doi.org/10.1073/pnas.90.8.3516 DO - 10.1073/pnas.90.8.3516 ID - Kozopas1993 ER - TY - JOUR AU - Thomas, L. W. AU - Lam, C. AU - Edwards, S. W. PY - 2010 DA - 2010// TI - Mcl-1; the molecular regulation of protein function JO - FEBS Lett VL - 584 UR - https://doi.org/10.1016/j.febslet.2010.05.061 DO - 10.1016/j.febslet.2010.05.061 ID - Thomas2010 ER - TY - JOUR AU - Papatzimas, J. W. AU - Gorobets, E. AU - Maity, R. AU - Muniyat, M. I. AU - MacCallum, J. L. AU - Neri, P. PY - 2019 DA - 2019// TI - From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1) JO - J Med Chem VL - 62 UR - https://doi.org/10.1021/acs.jmedchem.9b00455 DO - 10.1021/acs.jmedchem.9b00455 ID - Papatzimas2019 ER - TY - JOUR AU - Wang, Z. AU - He, N. AU - Guo, Z. AU - Niu, C. AU - Song, T. AU - Guo, Y. PY - 2019 DA - 2019// TI - Proteolysis targeting chimeras for the selective degradation of Mcl-1/Bcl-2 derived from nonselective target binding ligands JO - J Med Chem VL - 62 UR - https://doi.org/10.1021/acs.jmedchem.9b00919 DO - 10.1021/acs.jmedchem.9b00919 ID - Wang2019 ER - TY - JOUR AU - Wu, M. AU - Li, C. AU - Zhu, X. PY - 2018 DA - 2018// TI - FLT3 inhibitors in acute myeloid leukemia JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0675-4 DO - 10.1186/s13045-018-0675-4 ID - Wu2018 ER - TY - JOUR AU - Smith, C. C. AU - Wang, Q. AU - Chin, C. -. S. AU - Salerno, S. AU - Damon, L. E. AU - Levis, M. J. PY - 2012 DA - 2012// TI - Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia JO - Nature VL - 485 UR - https://doi.org/10.1038/nature11016 DO - 10.1038/nature11016 ID - Smith2012 ER - TY - JOUR AU - Nguyen, B. AU - Williams, A. B. AU - Young, D. J. AU - Ma, H. AU - Li, L. AU - Levis, M. PY - 2017 DA - 2017// TI - FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.14539 DO - 10.18632/oncotarget.14539 ID - Nguyen2017 ER - TY - JOUR AU - Mizuki, M. AU - Fenski, R. AU - Halfter, H. AU - Matsumura, I. AU - Schmidt, R. AU - Müller, C. PY - 2000 DA - 2000// TI - Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways JO - Blood VL - 96 UR - https://doi.org/10.1182/blood.V96.12.3907 DO - 10.1182/blood.V96.12.3907 ID - Mizuki2000 ER - TY - STD TI - Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011;6(9):e25351. ID - ref82 ER - TY - JOUR AU - Burslem, G. M. AU - Song, J. AU - Chen, X. AU - Hines, J. AU - Crews, C. M. PY - 2018 DA - 2018// TI - Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion JO - J Am Chem Soc VL - 140 UR - https://doi.org/10.1021/jacs.8b10320 DO - 10.1021/jacs.8b10320 ID - Burslem2018 ER - TY - JOUR AU - Galoczova, M. AU - Coates, P. AU - Vojtesek, B. PY - 2018 DA - 2018// TI - STAT3, stem cells, cancer stem cells and p63 JO - Cellular & molecular biology letters VL - 23 UR - https://doi.org/10.1186/s11658-018-0078-0 DO - 10.1186/s11658-018-0078-0 ID - Galoczova2018 ER - TY - JOUR AU - Chen, Q. AU - Lv, J. AU - Yang, W. AU - Xu, B. AU - Wang, Z. AU - Yu, Z. PY - 2019 DA - 2019// TI - Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis JO - Theranostics VL - 9 UR - https://doi.org/10.7150/thno.35528 DO - 10.7150/thno.35528 ID - Chen2019 ER - TY - JOUR AU - D'Amico, S. AU - Shi, J. AU - Martin, B. L. AU - Crawford, H. C. AU - Petrenko, O. AU - Reich, N. C. PY - 2018 DA - 2018// TI - STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis JO - Genes Dev VL - 32 UR - https://doi.org/10.1101/gad.311852.118 DO - 10.1101/gad.311852.118 ID - D'Amico2018 ER - TY - JOUR AU - Zhuang, S. PY - 2013 DA - 2013// TI - Regulation of STAT signaling by acetylation JO - Cell Signal VL - 25 UR - https://doi.org/10.1016/j.cellsig.2013.05.007 DO - 10.1016/j.cellsig.2013.05.007 ID - Zhuang2013 ER - TY - JOUR AU - Zhou, H. AU - Bai, L. AU - Xu, R. AU - Zhao, Y. AU - Chen, J. AU - McEachern, D. PY - 2019 DA - 2019// TI - Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein JO - J Med Chem VL - 62 UR - https://doi.org/10.1021/acs.jmedchem.9b01530 DO - 10.1021/acs.jmedchem.9b01530 ID - Zhou2019 ER - TY - JOUR AU - Bai, L. AU - Zhou, H. AU - Xu, R. AU - Zhao, Y. AU - Chinnaswamy, K. AU - McEachern, D. AU - Chen, J. AU - Yang, C. -. Y. AU - Liu, Z. AU - Wang, M. PY - 2019 DA - 2019// TI - A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo JO - Cancer cell VL - 36 UR - https://doi.org/10.1016/j.ccell.2019.10.002 DO - 10.1016/j.ccell.2019.10.002 ID - Bai2019 ER - TY - JOUR AU - Alfert, A. AU - Moreno, N. AU - Kerl, K. PY - 2019 DA - 2019// TI - The BAF complex in development and disease JO - Epigenetics Chromatin VL - 12 UR - https://doi.org/10.1186/s13072-019-0264-y DO - 10.1186/s13072-019-0264-y ID - Alfert2019 ER - TY - JOUR AU - Buscarlet, M. AU - Krasteva, V. AU - Ho, L. AU - Simon, C. AU - Hébert, J. AU - Wilhelm, B. PY - 2014 DA - 2014// TI - Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-02-483495 DO - 10.1182/blood-2013-02-483495 ID - Buscarlet2014 ER - TY - JOUR AU - Farnaby, W. AU - Koegl, M. AU - Roy, M. J. AU - Whitworth, C. AU - Diers, E. AU - Trainor, N. PY - 2019 DA - 2019// TI - BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design JO - Nat Chem Biol VL - 15 UR - https://doi.org/10.1038/s41589-019-0294-6 DO - 10.1038/s41589-019-0294-6 ID - Farnaby2019 ER - TY - STD TI - Neklesa T, Snyder LB, Willard RR, Vitale N, Raina K, Pizzano J, et al. Abstract 5236: ARV-110: an androgen receptor PROTAC degrader for prostate cancer. Cancer Res. 2018;78(13 Supplement):5236. ID - ref93 ER - TY - STD TI - Flanagan J, Qian Y, Gough S, Andreoli M, Bookbinder M, Cadelina G, et al. Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. Cancer Res. 2019;79:P5-04-18. ID - ref94 ER - TY - JOUR AU - Robb, C. M. AU - Contreras, J. I. AU - Kour, S. AU - Taylor, M. A. AU - Abid, M. AU - Sonawane, Y. A. PY - 2017 DA - 2017// TI - Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC) JO - Chem Commun VL - 53 UR - https://doi.org/10.1039/C7CC03879H DO - 10.1039/C7CC03879H ID - Robb2017 ER - TY - JOUR AU - An, Z. AU - Lv, W. AU - Su, S. AU - Wu, W. AU - Rao, Y. PY - 2019 DA - 2019// TI - Developing potent PROTACs tools for selective degradation of HDAC6 protein JO - Protein & cell VL - 10 UR - https://doi.org/10.1007/s13238-018-0602-z DO - 10.1007/s13238-018-0602-z ID - An2019 ER - TY - JOUR AU - Fischer, E. S. AU - Böhm, K. AU - Lydeard, J. R. AU - Yang, H. AU - Stadler, M. B. AU - Cavadini, S. PY - 2014 DA - 2014// TI - Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide JO - Nature VL - 512 UR - https://doi.org/10.1038/nature13527 DO - 10.1038/nature13527 ID - Fischer2014 ER - TY - JOUR AU - Hardcastle, I. R. PY - 2007 DA - 2007// TI - Inhibitors of the MDM2-p53 interaction as anticancer drugs JO - Drugs Future VL - 32 UR - https://doi.org/10.1358/dof.2007.032.10.1131965 DO - 10.1358/dof.2007.032.10.1131965 ID - Hardcastle2007 ER - TY - JOUR AU - Zhang, L. AU - Riley-Gillis, B. AU - Vijay, P. AU - Shen, Y. PY - 2019 DA - 2019// TI - Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes JO - Mol Cancer Ther VL - 18 UR - https://doi.org/10.1158/1535-7163.MCT-18-1129 DO - 10.1158/1535-7163.MCT-18-1129 ID - Zhang2019 ER - TY - JOUR AU - Ottis, P. AU - Toure, M. AU - Cromm, P. M. AU - Ko, E. AU - Gustafson, J. L. AU - Crews, C. M. PY - 2017 DA - 2017// TI - Assessing different E3 ligases for small molecule induced protein ubiquitination and degradation JO - ACS Chem Biol VL - 12 UR - https://doi.org/10.1021/acschembio.7b00485 DO - 10.1021/acschembio.7b00485 ID - Ottis2017 ER - TY - JOUR AU - Jiang, Y. AU - Deng, Q. AU - Zhao, H. AU - Xie, M. AU - Chen, L. AU - Yin, F. PY - 2017 DA - 2017// TI - Development of stabilized peptide-based PROTACs against estrogen receptor α JO - ACS Chem Biol VL - 13 UR - https://doi.org/10.1021/acschembio.7b00985 DO - 10.1021/acschembio.7b00985 ID - Jiang2017 ER -